Full-Time

Principal System Engineer – Service Delivery Lead

Veeva Vault

Posted on 8/27/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
IT & Security (1)
Required Skills
Microsoft Azure
ServiceNow
AWS
Jenkins
Requirements
  • Doctorate Degree and 2 years of experience in Business, Engineering, IT or related field OR
  • Master’s degree with 8 - 10 years of experience in Business, Engineering, IT or related field OR
  • Bachelor’s degree with 10 - 14 years of experience in Business, Engineering, IT or related field OR
  • Diploma with 14 - 18 years of experience in Business, Engineering, IT or related field
  • 12+ years in service delivery/IT operations; 5+ years in regulated SaaS (life sciences preferred). Proven 24×7 ownership across multiple regions.
  • Hands-on L2/L3 support for Veeva Vault (apps and platform), strong familiarity with Vault release cadence and environments. Vault Admin I preferred.
  • Expert in ServiceNow (incident/change/problem, CMDB, reports).
  • Deep knowledge of SSO/SAML, SoD design, periodic access reviews, token/credential rotation, secrets management, and audit logging/retention.
  • Working command of CSV, 21 CFR Part 11, Annex 11; experience producing audit-ready evidence and closing CAPAs.
  • Able to operate CI/CD pipelines (Jenkins, GitLab, GitHub Actions) for deployment and rollback processes; has knowledge of automated test gates and sandbox refresh procedures. Does not require experience in authoring pipelines from the beginning.
  • Strong understanding of architecting and deployment strategies for integrations to Veeva Vault Platforms/Products
  • Expertise in system integration, including APIs, middleware tools, and data migration between Vault and other systems.
  • Extensive knowledge of enterprise architecture frameworks, technologies, and methodologies
  • Experience with data, change, and technology governance processes on the platform level
  • Experience working in agile methodology, including Product Teams and Product Development models
  • Experience with cloud-based architectures, AWS, Azure, or similar environments.
Responsibilities
  • Run the global command center for Vault: queue management, priority triage, on-call rotations, and support of major-incident management (MIM). Ensure clean hand-offs across shifts and locations. Maintain runbooks, knowledge base, and hypercare plans for tri-annual Vault releases.
  • Drive MTTD (Mean Time to Detect) and MTTR (Mean Time to Repair/Restore/Resolve) down via playbooks, automated smoke checks, and standard changes.
  • Conduct ongoing maintenance and periodic review of all playbooks.
  • Chair weekly Problem/RCA reviews; turn corrective actions into preventive changes. Own change calendars, CAB inputs, and post-release health checks.
  • Publish weekly SLA & trend dashboards (uptime, MTTR, change success rate, ticket aging, backlog health, reopen rate, P1 frequency). Establish SLOs/error budgets and escalate risks early.
  • Own user provisioning/de-provisioning, role/permission models, and periodic access reviews across all Vaults.
  • Enforce SoD (Segregation of Duties) controls, break-glass procedures, and joiner/mover/leaver automation.
  • Coordinate resource rotation schedules and monitor audit logs for anomalies.
  • Drive continuous improvement vendor service performance by identifying opportunities for innovation and efficiency
  • Design vendor service that can scale to meet growing business needs and performance demands
  • Always maintain validated operational states. Incorporate CSV checkpoints into modifications to ensure continuous audit readiness.
  • Partner with Security on log retention, alerts, incident drills, and CAPA follow-through.
  • Consume and operate the CI/CD and test-automation assets (VPK/CLI promotion, regression packs, sandbox refresh jobs).
  • Trigger rollbacks/hot fixes safely; raise pipeline improvements to the DevOps team with data.
  • Lead and coach team (across India and Amgen locations).
  • Hire, build skills, run shift rosters, conduct post-incident coaching, and set an accountable culture.
  • Provide subject matter expertise in Veeva Vault to the platform team, offering guidance on architecture, solution design, and implementation challenges.
  • Provide hands-on technical leadership in resolving complex technical issues and ensuring smooth deployment and system integration
  • Work with stakeholders to gather and analyze teams’s performance and service related KPIs, ensuring that service meet both business and technical needs.
Desired Qualifications
  • Good Knowledge of the Global Pharmaceutical Industry
  • Understanding of GxP process
  • Strong solution design and problem-solving skills
  • Strong understanding of technology, function, or platform
  • Experience in developing differentiated and deliverable solutions
  • Ability to analyze client requirements and translate them into solutions
  • Working late hours

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE